CA2269994A1 - 7-hetero-bicyclo¬2.2.1|-heptanes - Google Patents
7-hetero-bicyclo¬2.2.1|-heptanes Download PDFInfo
- Publication number
- CA2269994A1 CA2269994A1 CA002269994A CA2269994A CA2269994A1 CA 2269994 A1 CA2269994 A1 CA 2269994A1 CA 002269994 A CA002269994 A CA 002269994A CA 2269994 A CA2269994 A CA 2269994A CA 2269994 A1 CA2269994 A1 CA 2269994A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- heptanes
- bicyclo
- hetero
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Disclosed are compounds of the formula:
(see formula I) (wherein R1, R2, R3 and R4 are each H, -CO2R5, optionally substituted aryl or optionally substituted heteroaryl; R5 is alkyl, aryl, arylalkyl or heteroarylalkyl; and R6 is H or alkyl) and their pharmaceutically acceptable salts, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
(see formula I) (wherein R1, R2, R3 and R4 are each H, -CO2R5, optionally substituted aryl or optionally substituted heteroaryl; R5 is alkyl, aryl, arylalkyl or heteroarylalkyl; and R6 is H or alkyl) and their pharmaceutically acceptable salts, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8310898P | 1998-04-27 | 1998-04-27 | |
US60/083,108 | 1998-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2269994A1 true CA2269994A1 (en) | 1999-10-27 |
CA2269994C CA2269994C (en) | 2003-03-18 |
Family
ID=22176228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002269994A Expired - Fee Related CA2269994C (en) | 1998-04-27 | 1999-04-23 | 7-hetero-bicyclo¬2.2.1|-heptanes |
Country Status (5)
Country | Link |
---|---|
US (3) | US20020038028A1 (en) |
EP (1) | EP0955301A3 (en) |
JP (2) | JPH11322751A (en) |
BR (1) | BR9901491A (en) |
CA (1) | CA2269994C (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ500642A (en) | 1997-05-30 | 2001-11-30 | Neurosearch As | 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
CZ301925B6 (en) * | 1997-12-31 | 2010-08-04 | Pfizer Products Inc. | Azapolycyclic derivatives containing annellated aryl group, their use, pharmaceutical compositions based thereon as well as intermediates for their preparation |
ATE353328T1 (en) * | 1999-11-12 | 2007-02-15 | Biogen Idec Inc | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS FOR THEIR PRODUCTION AND USE |
EA005211B1 (en) * | 1999-11-12 | 2004-12-30 | Байоджен, Инк. | Polycycloalkylpurines as adenosine receptor antagonists |
US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6579878B1 (en) * | 2000-07-07 | 2003-06-17 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6538010B1 (en) | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
JP2005504058A (en) * | 2001-08-24 | 2005-02-10 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Substituted heteroaryl-7-aza [2.2.1] bicycloheptane for the treatment of disease |
MXPA04002539A (en) * | 2001-10-31 | 2004-05-31 | Pfizer Prod Inc | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome. |
BR0214578A (en) | 2001-11-30 | 2004-11-03 | Pfizer Prod Inc | Azopolyclic compounds fused with aryl |
MXPA05008108A (en) * | 2003-02-21 | 2005-09-21 | Pharmacia & Upjohn Co Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them. |
CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
US7718677B2 (en) | 2007-04-02 | 2010-05-18 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
EP2203439B1 (en) | 2007-09-14 | 2011-01-26 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones |
CA2638573C (en) | 2008-04-30 | 2013-03-12 | Universiteit Gent | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions |
US8389561B2 (en) | 2008-04-30 | 2013-03-05 | Universiteit Gent | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
BRPI0921333A2 (en) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | indole and benzoxazine derivatives as metabotropic glutamate receptor modulators |
PL2430022T3 (en) | 2009-05-12 | 2014-02-28 | Janssen Pharmaceuticals Inc | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8809365B2 (en) | 2009-11-04 | 2014-08-19 | Universiteit Gent | 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders |
ES2576282T3 (en) | 2010-08-20 | 2016-07-06 | Research Triangle Institute | Compounds that act on nicotinic receptors |
CN103298809B (en) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-triazol [4,3-a] pyridine derivate and the purposes of the positive allosteric modulators as MGLUR2 acceptor thereof |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
PT2649069E (en) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CN102633804B (en) * | 2012-04-19 | 2014-09-24 | 中南大学 | Method for preparing 7-Azabicyclo[2.2.1]heptane |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
ES2860298T3 (en) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use |
EA033889B1 (en) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Combination comprising sv2a ligand and positive allosteric modulator of metabotropic glutamatergic receptor subtype 2 |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Device and method for transdermal drug delivery |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314899A (en) * | 1992-03-03 | 1994-05-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Epibatidine and derivatives, compositions and methods of treating pain |
WO1994022868A1 (en) * | 1993-04-01 | 1994-10-13 | University Of Virginia | 7-azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents |
US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
JP3637973B2 (en) * | 1993-06-17 | 2005-04-13 | エーザイ株式会社 | Azabicycloheptane derivatives |
AU7474794A (en) * | 1993-07-22 | 1995-02-20 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
US6077846A (en) * | 1993-09-10 | 2000-06-20 | Ucb, S.A. | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
BE1008622A3 (en) * | 1993-12-09 | 1996-06-04 | Egyt Gyogyszervegyeszeti Gyar | DERIVATIVES The EPI-Epibatidine. |
EP0664293A1 (en) * | 1993-12-24 | 1995-07-26 | Duphar International Research B.V | 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo |
JP2001521523A (en) * | 1997-04-11 | 2001-11-06 | アボツト・ラボラトリーズ | Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission |
-
1999
- 1999-03-25 EP EP99302306A patent/EP0955301A3/en not_active Withdrawn
- 1999-04-20 JP JP11112125A patent/JPH11322751A/en not_active Withdrawn
- 1999-04-23 CA CA002269994A patent/CA2269994C/en not_active Expired - Fee Related
- 1999-04-26 BR BR9901491-2A patent/BR9901491A/en not_active IP Right Cessation
-
2001
- 2001-10-10 JP JP2001312656A patent/JP2002114679A/en active Pending
- 2001-11-21 US US09/988,950 patent/US20020038028A1/en not_active Abandoned
- 2001-11-21 US US09/988,949 patent/US20020035262A1/en not_active Abandoned
-
2003
- 2003-02-27 US US10/375,630 patent/US20030236405A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0955301A2 (en) | 1999-11-10 |
JPH11322751A (en) | 1999-11-24 |
JP2002114679A (en) | 2002-04-16 |
US20020038028A1 (en) | 2002-03-28 |
BR9901491A (en) | 2000-05-02 |
CA2269994C (en) | 2003-03-18 |
EP0955301A3 (en) | 2001-04-18 |
US20030236405A1 (en) | 2003-12-25 |
US20020035262A1 (en) | 2002-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2269994A1 (en) | 7-hetero-bicyclo¬2.2.1|-heptanes | |
CA2316921A1 (en) | Aryl fused azapolycyclic compounds | |
CA2401229A1 (en) | Aryl fused azapolycyclic compounds | |
CA2258548A1 (en) | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases | |
CA2216796A1 (en) | Quinazoline derivatives | |
CA2102179A1 (en) | Quinuclidine derivatives | |
CA2272705A1 (en) | Fused bicyclic pyrimidine derivatives | |
CA2119647A1 (en) | Heteroaryl Amines as Novel Acetylcholinesterase Inhibitors | |
AP2002002637A0 (en) | Novel piperazine | |
CA2152486A1 (en) | Anticonvulsant sorbopyranose sulfamates | |
CA2160444A1 (en) | Aroyl-piperdine derivatives | |
CA2240138A1 (en) | Quinazolin-4-one ampa antagonists | |
CA2445306A1 (en) | Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives | |
CA2280447A1 (en) | Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands | |
CA2333703A1 (en) | Isothiazole derivatives useful as anticancer agents | |
IL162498A0 (en) | (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same | |
NO996108L (en) | 9 oksinerytromycinderivater | |
CA2260213A1 (en) | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists | |
CA2373117A1 (en) | 13-methyl-erythromycin derivatives | |
CA2156078A1 (en) | New imidazopyridines | |
CA2176935A1 (en) | Indole-derived azylpiperazines as ligands for 5ht1-like receptors 5ht1b and 5ht1d | |
MY133474A (en) | Aryl fused azapolycyclic compounds | |
CA2286511A1 (en) | Novel macrolide derivatives | |
IT1307267B1 (en) | PROCEDURE FOR THE STRENGTHENING OF ANTI-TUMOR ACTIVITIES OF FARMACIGREZZI, COMPOSITION CONTAINING A RAW STRENGTHENING DRUG | |
AU7581394A (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |